Greenwich Pharmaceuticals Inc. has initiated Phase I humansafety trials to test GW92527.HCL as an oral treatment forrheumatoid arthritis. GW92527.HCL is the company's third in anew category of synthetic carbohydrate compounds beingdeveloped for this disease. In preclinical studies it hasexhibited immunomodulatory, anti-inflammatory, andanalgesic activities.

Greenwich of Fort Washington, Penn., has two other syntheticcarbohydrate compounds, Therafectin (amiprilose HCL) andGW80126, in more advanced stages of development for chronictreatment of rheumatoid arthritis.

(c) 1997 American Health Consultants. All rights reserved.